tiprankstipranks
Immutep (IMMP)
NASDAQ:IMMP

Immutep (IMMP) AI Stock Analysis

Compare
651 Followers

Top Page

IM

Immutep

(NASDAQ:IMMP)

50Neutral
Immutep's overall stock score of 50 reflects a balance of financial challenges and stable technical indicators. The company's strong equity position and ability to secure financing are positive, but ongoing losses and the lack of profitability weigh heavily. The technical outlook is neutral, and the absence of recent corporate events or earnings call insights limits further assessment.
Positive Factors
Clinical Trial Success
Immutep reported positive updated data from cohort B of the P2b TACTI-003 study evaluating efti + Keytruda in 1L head & neck cancer with negative PD-L1 expression, showing promising results.
Survival Rate
The study data for efti + Keytruda reports a 67% 12-month overall survival rate, which is significantly higher compared to historical results for Keytruda monotherapy.
Negative Factors
Market Competition
The 1L metastatic HNSCC space has become very competitive.

Immutep (IMMP) vs. S&P 500 (SPY)

Immutep Business Overview & Revenue Model

Company DescriptionImmutep (IMMP) is a biotechnology company focused on developing novel immunotherapy treatments for cancer and autoimmune diseases. The company operates primarily in the healthcare and biotechnology sectors, with a core focus on leveraging its proprietary technology to modulate the immune system. Immutep's lead product candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance the immune response in cancer patients. In addition to eftilagimod alpha, Immutep is advancing other therapeutic candidates in its pipeline, including IMP761 for autoimmune diseases and partnerships involving LAG-3 products.
How the Company Makes MoneyImmutep primarily generates revenue through a combination of licensing agreements, collaborative research, and development partnerships. The company partners with other pharmaceutical and biotechnology companies to co-develop and commercialize its therapeutic candidates. Revenue streams include upfront payments, milestone payments, and royalties from these partnerships. Immutep's collaborations with major industry players, such as Merck and GlaxoSmithKline, play a crucial role in its revenue generation strategy by providing funding and expertise to advance its product pipeline. Additionally, Immutep may receive government grants and financial support to aid in the development of its immunotherapy treatments.

Immutep Financial Statement Overview

Summary
Immutep's financial performance reflects challenges typical for development-phase biotech firms. The income statement shows ongoing losses with negative margins, while the balance sheet is stable due to strong equity and low leverage. Cash flow issues persist due to high R&D costs, but are partially mitigated by effective financing strategies.
Income Statement
42
Neutral
Immutep displays a challenging income statement with a negative gross profit margin and consistently negative net income. Revenue growth has been volatile, with recent growth from a low base. The EBIT and EBITDA margins are deeply negative, reflecting ongoing operational and structural challenges. The company’s financial trajectory indicates difficulty in achieving profitability in the near term, common in biotechs during extensive R&D phases.
Balance Sheet
58
Neutral
The balance sheet shows a strong equity position with low debt levels, resulting in a favorable debt-to-equity ratio. The equity ratio is robust, highlighting financial stability and a solid asset base. However, the continuous losses and cash burn could pressure equity if not offset by ongoing financing activities, a typical scenario in the biotechnology sector.
Cash Flow
50
Neutral
Cash flow analysis reveals negative operating and free cash flows as expected in an R&D-intensive biotech firm. Operating cash flow to net income ratio is not favorable, indicating significant cash burn relative to revenue generation. Free cash flow remains negative, but the company has managed significant financing to support operations, a critical factor for sustaining R&D activities.
Breakdown
Jun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
3.84M3.51M170.37K3.97M7.49M
Gross Profit
-37.70M1.44M-1.89M1.90M-14.99M
EBIT
-88.10M-44.94M-33.94M-19.56M-16.02M
EBITDA
-44.54M-39.57M-31.87M-17.77M-13.46M
Net Income Common Stockholders
-42.72M-39.90M-32.21M-29.90M-13.47M
Balance SheetCash, Cash Equivalents and Short-Term Investments
181.88M123.42M80.00M60.13M26.32M
Total Assets
201.58M147.45M102.17M82.03M46.60M
Total Debt
1.59M1.23M1.73M2.82M9.05M
Net Debt
-160.20M-122.19M-78.26M-57.31M-17.27M
Total Liabilities
12.06M10.98M8.09M8.76M13.30M
Stockholders Equity
189.52M136.47M94.08M73.27M33.30M
Cash FlowFree Cash Flow
-35.75M-35.93M-30.25M-17.66M-10.86M
Operating Cash Flow
-34.82M-35.88M-30.23M-17.64M-10.84M
Investing Cash Flow
-21.02M-31.00K-22.91K-15.60K-19.35K
Financing Cash Flow
95.18M76.04M50.33M52.68M20.48M

Immutep Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.70
Price Trends
50DMA
1.96
Negative
100DMA
1.97
Negative
200DMA
2.14
Negative
Market Momentum
MACD
-0.07
Positive
RSI
31.74
Neutral
STOCH
5.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMMP, the sentiment is Negative. The current price of 1.7 is below the 20-day moving average (MA) of 1.88, below the 50-day MA of 1.96, and below the 200-day MA of 2.14, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 31.74 is Neutral, neither overbought nor oversold. The STOCH value of 5.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMMP.

Immutep Risk Analysis

Immutep disclosed 52 risk factors in its most recent earnings report. Immutep reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Immutep Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
$3.88B-31.41%49.59%24.92%
58
Neutral
$5.90B266.6912.21%40.80%100.62%
53
Neutral
$881.05M-50.50%4.28%
50
Neutral
$253.13M-31.16%15.17%
49
Neutral
$6.90B0.02-54.05%2.46%24.91%-3.14%
42
Neutral
$110.00M-54.21%-78.55%-0.92%
38
Underperform
$48.09M260.68%59.00%32.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IMMP
Immutep
1.70
-0.82
-32.54%
AGEN
Agenus
1.86
-10.13
-84.49%
FATE
Fate Therapeutics
1.01
-6.22
-86.03%
TGTX
TG Therapeutics
37.23
21.87
142.38%
ZLAB
Zai Lab
35.43
15.88
81.23%
REPL
Replimune Group
12.11
3.27
36.99%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.